TY - JOUR T1 - Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN JF - European Respiratory Journal JO - Eur Respir J VL - 38 IS - Suppl 55 SP - p877 AU - Paul W. Jones AU - Alvar Agusti AU - Eric D. Bateman AU - David Singh AU - Rosa Lamarca AU - Gonzalo de Miquel AU - Cynthia Caracta AU - Esther Garcia Gil Y1 - 2011/09/01 UR - http://erj.ersjournals.com/content/38/Suppl_55/p877.abstract N2 - Introduction: The ATTAIN study investigated the efficacy and safety of two twice-daily doses of aclidinium bromide, a long-acting muscarinic antagonist, in patients with moderate to severe chronic obstructive pulmonary disease (COPD).Methods: In this 24-week, double-blind trial, patients were randomised (1:1:1) to receive aclidinium (200 μg or 400 μg) or placebo, twice-daily. Health status was assessed using the St George's Respiratory Questionnaire (SGRQ) and the EuroQol Questionnaire (EQ-5D; both the weighted health status index and the visual analogue scale [VAS]).Results: There were 819 patients in the intent-to-treat population; forced expiratory volume in 1 second [FEV1%] predicted 56.8±12.8%, baseline SGRQ total score 46.3±16.8 units. At Week 24, more patients had a clinically significant improvement in SGRQ total score (decrease of ≥4 units) with aclidinium 200 μg and 400 μg than placebo (54.9% and 54.3% vs 39.5%; p=0.0004 and 0.0014, respectively). At Week 24, the improvement with aclidinium 400 μg was 4.3 units, p<0.0001. SGRQ domain scores (Symptoms, Activity, Impacts) were also significantly improved with both doses vs placebo at Week 24 (p<0.05 all domains). Aclidinium 200 μg and 400 μg also improved the EQ-5D weighted index and VAS compared with placebo at Week 24; the 400 μg dose reached statistical significance for the weighted index (p=0.041) and VAS (p=0.005) vs placebo.Conclusions: Aclidinium 200 μg and 400 μg twice-daily provided statistically and clinically significant improvements in health status.This study was supported by Almirall S.A., Barcelona, Spain, and Forest Laboratories, Inc, New York, USA. ER -